HUE058314T2 - Pridopidin alkalmazása Rett-szindróma kezelésére - Google Patents

Pridopidin alkalmazása Rett-szindróma kezelésére

Info

Publication number
HUE058314T2
HUE058314T2 HUE17851614A HUE17851614A HUE058314T2 HU E058314 T2 HUE058314 T2 HU E058314T2 HU E17851614 A HUE17851614 A HU E17851614A HU E17851614 A HUE17851614 A HU E17851614A HU E058314 T2 HUE058314 T2 HU E058314T2
Authority
HU
Hungary
Prior art keywords
pridopidine
treatment
rett syndrome
rett
syndrome
Prior art date
Application number
HUE17851614A
Other languages
English (en)
Hungarian (hu)
Inventor
Michal Geva
Ralph Laufer
Michael Hayden
Original Assignee
Prilenia Neurotherapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prilenia Neurotherapeutics Ltd filed Critical Prilenia Neurotherapeutics Ltd
Publication of HUE058314T2 publication Critical patent/HUE058314T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
HUE17851614A 2016-09-16 2017-09-15 Pridopidin alkalmazása Rett-szindróma kezelésére HUE058314T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662395854P 2016-09-16 2016-09-16

Publications (1)

Publication Number Publication Date
HUE058314T2 true HUE058314T2 (hu) 2022-07-28

Family

ID=61619744

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE17851614A HUE058314T2 (hu) 2016-09-16 2017-09-15 Pridopidin alkalmazása Rett-szindróma kezelésére

Country Status (13)

Country Link
EP (2) EP4005570B1 (enExample)
JP (1) JP6977029B2 (enExample)
CN (1) CN109982686A (enExample)
AU (1) AU2017326013B2 (enExample)
BR (1) BR112019005040A2 (enExample)
CA (1) CA3036984C (enExample)
DK (2) DK4005570T3 (enExample)
ES (2) ES2909557T3 (enExample)
HU (1) HUE058314T2 (enExample)
IL (1) IL265342B2 (enExample)
MX (1) MX388845B (enExample)
PL (2) PL3512506T3 (enExample)
WO (1) WO2018053280A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11090297B2 (en) 2013-06-21 2021-08-17 Prilenia Neurotherapeutics Ltd. Pridopidine for treating huntington's disease
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
CN110012661A (zh) 2016-08-24 2019-07-12 普瑞尼亚医疗发展有限公司 普利多匹定用于治疗肌张力障碍的用途
IL311081A (en) 2016-08-24 2024-04-01 Prilenia Neurotherapeutics Ltd Use of pyridofidine to treat functional decline
US12102627B2 (en) 2016-09-16 2024-10-01 Prilenia Neurotherapeutics Ltd. Use of pridopidine for treating rett syndrome
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett
US12036213B2 (en) 2017-09-08 2024-07-16 Prilenia Neurotherapeutics Ltd. Pridopidine for treating drug induced dyskinesias
JP2022524927A (ja) 2019-02-02 2022-05-11 ステモニックス インコーポレイティド 創薬のためのヒトスフェロイドの使用方法
JP7585561B2 (ja) 2019-02-04 2024-11-19 プリレニア ニューロセラピューティクス リミテッド パーキンソン病およびパーキンソニズムに関連する他の疾患のための低用量プリドピジン
AU2020243692B2 (en) 2019-03-15 2023-03-02 Prilenia Neurotherapeutics Ltd. Treatment of mitochondrial associated diseases and disorders, including symptoms thereof using pridopidine
CN116472043A (zh) * 2020-10-20 2023-07-21 普瑞尼亚神经治疗有限公司 普利多匹定和类似物用于治疗焦虑和抑郁的用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9904724D0 (sv) * 1999-12-22 1999-12-22 Carlsson A Research Ab New modulators of dopamine neurotransmission I
ES2659577T3 (es) 2004-10-13 2018-03-16 Teva Pharmaceuticals International Gmbh Proceso para la síntesis de 4-(3-metanosulfonilfenil)-1-N-propil-piperidina
NZ608120A (en) 2010-09-03 2014-12-24 Ivax Int Gmbh Deuterated analogs of pridopidine useful as dopaminergic stabilizers
EP2787997A4 (en) * 2011-12-08 2015-05-27 Ivax Int Gmbh HYDROBROMIDE SALT OF PRIDOPIDINE
BR112014024672A8 (pt) 2012-04-04 2018-04-03 Ivax Int Gmbh Composições farmacêuticas para terapia de combinação
CA2913781C (en) 2013-06-21 2022-05-10 Teva Pharmaceutical Industries Ltd. Use of pridopidine for treating huntington's disease
CA2937243C (en) * 2014-01-22 2023-07-18 Teva Pharmaceuticals International Gmbh Modified release formulations of pridopidine
EP3854785A1 (en) * 2015-02-25 2021-07-28 Prilenia Neurotherapeutics Ltd. Use of pridopidine to treat depression or anxiety
WO2016138135A1 (en) * 2015-02-25 2016-09-01 Teva Pharmaceuticals International Gmbh Sigma-1 receptor modulators for treating huntington's disease
ES2909557T3 (es) 2016-09-16 2022-05-09 Prilenia Neurotherapeutics Ltd Utilización de la pridopidina para el tratamiento del síndrome de Rett

Also Published As

Publication number Publication date
MX2019003069A (es) 2019-09-02
PL3512506T3 (pl) 2022-05-30
EP4005570A1 (en) 2022-06-01
DK3512506T3 (da) 2022-04-19
CN109982686A (zh) 2019-07-05
MX388845B (es) 2025-03-20
BR112019005040A2 (pt) 2019-07-16
AU2017326013B2 (en) 2020-12-24
EP3512506A1 (en) 2019-07-24
JP6977029B2 (ja) 2021-12-08
DK4005570T3 (da) 2024-08-19
EP4005570B1 (en) 2024-05-15
EP3512506B1 (en) 2022-01-26
AU2017326013A1 (en) 2019-04-11
ES2986807T3 (es) 2024-11-12
CA3036984A1 (en) 2018-03-22
IL265342A (en) 2019-05-30
EP3512506A4 (en) 2020-05-27
WO2018053280A1 (en) 2018-03-22
PL4005570T3 (pl) 2024-09-23
JP2019532926A (ja) 2019-11-14
CA3036984C (en) 2023-07-18
IL265342B2 (en) 2023-06-01
ES2909557T3 (es) 2022-05-09

Similar Documents

Publication Publication Date Title
IL283086A (en) Use of cannabidiol in the treatment of tuberous sclerosis complex
IL259441A (en) Materials and methods for treatment of titin-based myopathies and other titinopaties
GB2548873B (en) Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
IL279751B (en) Polycyclic compounds and use thereof in the treatment of immune disorders
EP3463464A4 (en) ASSOCIATION TREATMENT
IL249292A0 (en) Methods and devices for treating pulmonary edema
GB201621480D0 (en) Use of cannabinoids in the treatment of angelman syndrome
HUE062189T2 (hu) Aktivin-ACTRII-antagonisták és alkalmazások mielodiszpláziás szindróma kezelésére
PL3157512T3 (pl) Zastosowanie kannabidioli w leczeniu padaczki
LT3240554T (lt) Blautia stercosis ir wexlerae, skirtos naudoti uždegiminių ir autoimuninių ligų gydymui
HUE061761T2 (hu) Tetrahidropiranil-amino-pirrolopirimidinon felhasználásra BTK-által közvetített zavarok kezelésében
EP3564335A4 (en) SURFACE TREATMENT AGENT
PL3503890T3 (pl) Stosowanie pridopidyny w leczeniu dystonii
LT3105253T (lt) Antikūnai prieš jagged1 ir jų naudojimo būdai
DK3015526T3 (da) Hydrofluorolefinbaseret sammensætning og anvendelse deraf
DK3481846T3 (da) 11-substituerede 24-hydroxysteroler til anvendelse til behandling af nmda-relaterede tilstande
EP3334429C0 (en) HYPERPHENYLALANINEMIA AND TREATMENTS THEREFOR
HRP20180260T1 (hr) Dimer buprenorfina i njegova uporaba u liječenju gastrointestinalnih poremećaja
PL3236960T3 (pl) Fluralaner do zastosowania w leczeniu demodekozy
DK3164123T3 (da) Hidtil ukendte anvendelser af benzylidenguanidinderivater til behandling af proteopatier
IL251904B (en) Apilimod for use in the treatment of melanoma
DK3710000T3 (da) Tradipitant til anvendelse til behandling af gastroparese
PL3229794T3 (pl) Kombinacja farmaceutyczna obejmująca ponesimod i jej zastosowanie w leczeniu stwardnienia rozsianego
DK3374497T3 (da) Modificerede makrofager til anvendelse i behandlingen af kræft
PL4005570T3 (pl) Pridopidyna do zastosowania w leczeniu zespołu retta